Emerging data is showing that treatment within 6 months of presentation of multiple sclerosis (MS) is ideal, explained Patricia K. Continue reading →

A new study suggeststhe need for caution in switching from fingolimod to a B celldepleting anti-CD20 treatment such as ocrelizumab for patients with multiple sclerosis (MS). Italian researchers report an increased risk for prolonged reductions in T-cell counts, in addition to depletion of B cells, among patients who make this switch. Such depletion could increase the risk for infection, a particular concern in the current COVID era Continue reading →

Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continuedthis week with a court ruling thatclears the way for more copycat drugs to launch. After the Delaware patent court loss this week, multiple generics will likely roll out soon, Bernstein analyst Ronny Galpredictsand when they do, they'll siphon off most of Tecfidera's $3 billion-plus in U.S. Continue reading →

The following article is part of conference coverage from the 8th Joint American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) MSVirtual2020 event. Neurology Advisors staff will be reporting breaking news associated with research conducted by leading experts in neurology. Continue reading →

Marthas Vineyard Hospital leaders urged Vineyarders to not postpone care and to schedule flu shots as the fall begins, breathing a sigh of relief about the summer but preparing for the unknown months that lie ahead for homelessness and drug use prevention. During the hospitals biweekly press briefing Wednesday morning, president and chief executive officer Denise Schepici said there is evidence that patients are postponing care and arriving at the hospital with acute illnesses that require treatment off-Island. Continue reading →